Oryzon Genomics - Key €45m funding to back strategic priorities
Oryzon has secured funding of up to €45m through a revised convertible bond financing agreement with Nice & Green, a Switzerland-based...
354 Views
Oryzon Genomics - Q323 recap ahead of key clinical stages
Oryzon’s Q323 results recapped the clinical progression across its drug development pipeline. The company continues to develop therapies that...
363 Views
Oryzon Genomics - Favorable safety reported in PORTICO Phase II
Oryzon presented a positive update on vafidemstat’s ongoing Phase IIb PORTICO trial in borderline personality disorder (BPD) at the ECNP Congress....
301 Views
Oryzon Genomics - Grants provide confidence and expand portfolio
Oryzon has announced that it has received two separate grants from the Spanish State Research Agency and the Ministry of Science and Innovation to...
369 Views
Oryzon Genomics - H123 progress and results came in as expected
Oryzon’s H123 results highlight the continued progress of its lead clinical-stage assets, including positive aggregate safety data from the Phase...
345 Views